Study Analysis: High Percentage of Blood Disorder Patients Were Cured
or Achieved Remission When Treated with Stem Cells from Their Own
Cord Blood or a Sibling's
Print article
Refer to a friend
© Business Wire 2008
2008-02-14 14:54:23 -
www.cordblood.
1420 x1462 Cell: 650-544-6890 lzobkiw@cordblood.
Cell: 650-235-0234 dzitlow@cordblood.
blood disorder patients treated with stem cells from their own cord
blood (autologous transplant) or from the cord blood of a sibling
(allogeneic-
were cured or achieved remission from their disease, according to a
report presented today at the American Society for Blood and Marrow
Treatment (ASBMT) annual meeting.
"This study provides important insights into the ability of
transplant physicians to achieve successful outcomes using an
individual's own cord blood to treat an environmentally-
blood disease or cord blood from a family member to treat certain
genetic blood disorders and inherited bone marrow failure syndromes
(IBMFs)," said Dr. Jennifer Willert, senior attending transplant
physician and clinical professor at Rady Children's Hospital,
University of California - San Diego, and lead author of this
study. "In addition, this data suggests that the use of genetically-
related cord blood may reduce the rate of mortality as well as the
risk of treatment-related complications.
The analysis examined transplant recipient data from 16 cases of
nonmalignant blood disorders. Four of the patients were infused with
their own cord blood stem cells to treat aplastic anemia, an acquired
condition. Twelve patients were transplanted with cord blood stem
cells of a sibling for a range of inherited conditions including,
thalassemia, sickle cell anemia, Fanconi anemia and Hurler syndrome.
The review showed that two-thirds of the patients (10) are either
cured or in remission, including half of the patients treated with
their own cord blood. Three patients died of complications unrelated
to their cord blood transplant; one patient experienced a relapse;
and the outcomes status of two patients is not known.
All 16 cord blood collections were processed and cryopreserved at
Cord Blood Registry and were viable for transplant when requested.
The average storage time prior to use was about 27 months; however,
one child's collection was stored for nine and half years and used to
successfully cure that child's aplastic anemia (autologous use).
Advantages of Genetically-
According to previously published data, transplantation of
genetically-
advantages over bone marrow, peripheral blood and unrelated umbilical
cord blood. Since cord blood stem cells are immunologically younger
than other "adult" stem cell sources, they demonstrate more
versatility and flexibility when used in transplantation. Stem cell
transplants from genetically-
family member) result in better treatment outcomes than transplants
from an unrelated donor and are associated with less frequent and
less severe graft-vs.-host disease, a complication that occurs when
the donor cells attack different parts of the body. Cord blood is
rapidly becoming a preferred stem cell source in transplant therapy,
with more than 10,000 cord blood transplants performed worldwide to-
date.
"This study is relevant to any expectant parent considering whether
or not to privately bank cord blood stem cells," said
Willert. "Individuals who have access to their own cord blood stem
cells, as well as a sibling's, have the best chance of treating a
blood disorder that develops. For expectant parents who already have
a family member with a diagnosed blood disorder that can be treated
by cord blood stem cells, it's important to know that there are free
cord blood banking programs available - known as related donor or
designated transplant programs - that provide immediate access to the
genetically-
About Cord Blood Registry's Designated Transplant Program
Related donor programs - such as Cord Blood Registry's Designated
Transplant Program(R), offer expectant parents the opportunity to
bank the cord blood of their newborn at no cost when another family
member has been diagnosed with a condition that may require a stem
cell transplant. The first charitable cord blood banking program of
its kind, CBR's Designated Transplant Program was launched in 1996
and currently has nearly 2,000 newborns that have been accepted into
the program. For a family to qualify for the program, the designated
recipient of the cord blood stem cells must be diagnosed with a
disease currently treated with a stem cell transplant and be a first-
or second-degree blood relative to the newborn (sibling, half-
sibling, parent, grandparent, aunt or uncle). Additionally, the
recipient's physician must verify that the stem cells may be used for
treatment. For qualified families, CBR will process and store the
cord blood stem cells of the newborn in the family at no cost until
they are needed for transplant.
About Cord Blood Registry
Cord Blood Registry(R) (CBR(R)) is the world's largest cord blood
stem cell processing and cryopreservation service and offers families
guaranteed access to genetically-
for medical use. CBR was the first family bank accredited by AABB and
is the most recommended cord blood bank by obstetricians. To date,
CBR has processed and stored cord blood collections for more than
200,000 newborns throughout the world and has released more than 65
client cord blood units for specific therapeutic use - more than any
other family cord blood bank. The company's research and development
efforts are focused on helping the world's leading researchers
advance regenerative medical therapies using cord blood stem cells as
well as continuing to introduce industry-leading technical
innovations for stem cell collection, processing and storage that
optimize quality and cell yield. Additionally, CBR facilitates
collection of donated samples, available for research programs
worldwide that are focused on stem cell expansion and other cord
blood stem cell-based therapies. For more information about CBR,
visit www.CordBlood.
Data Presented at Major Medical Meeting Also Highlights Low Risk
of Transplant-Related Complications with Genetically-
Blood Stem Cells
http://www.pr-
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
